Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
150 participants
INTERVENTIONAL
2019-10-10
2021-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Groupe A takes into account the lipid and protein content in addition to the carbohydrate content
* Group B takes into account the carbohydrate content only At randomization, all patients receive dietary and adjustment of bolus doses instructions according to the randomization group. They have to apply these instructions for 3 months. At the end of 3 months, the study groups will be under glucose monitoring during two weeks in the Outpatient Clinic but returns to the investigational site in hospital to download data from the continuous measurement of glucose. In addition, we propose a period of extension similar to that of the main period, namely 3 months of application of dietetic and adaptation of bolus doses instructions and 2 weeks of continuous measurement of glucose.
During each 2 weeks period will be assessed specific glucose parameters in the post-prandial period over 4hours (glycemic sensor values in the glucose range between 70-140 mg / dl, glycemic sensor values in the glucose range between 140 -180 mg /dl and \> 180 mg /dl) after taking each meal during the 13 days of Glucose Continuous Measurement (GCM), average daily glucose per meal, average blood glucose over the 13-day period after each meal.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Normal Versus Dual Wave Insulin Bolus for High-protein Food
NCT02276859
Insulin Delivery Using the DBLG1 Closed-loop on Glycemic Control and PROMs in Adults Living With Type 1 Diabetes
NCT06154135
Real-life Follow-up of the Physical Activity in Type 1 Diabetes Participants Equipped With an Insulin Pump With Hybrid Closed Loop
NCT07015970
Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients
NCT02229097
Insulin in Total Parenteral Nutrition
NCT02706119
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
New functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
Group B
Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
New functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient treated with external insulin pump (Medtronic or Omnipod pump)
* Patient performing intermittent blood glucose monitoring by the continuous interstitial glucose measurement system (Freestyle Libre) and who regularly wears this device with an achievement of at least 4 scans per day to obtain at least 90% of the possible values
* Patient with HbA1c ≤10.0% less than 3 months
* Patient with a willingness and ability to comply with study requirements and schedule of visits
* Patient who received complete information and signed informed consent
Exclusion Criteria
* Patient for whom a change of insulin in the next 3 to 6 months is planned
* Women of childbearing age who do not have effective contraception
* Women who are pregnant or breast feeding or plan on becoming pregnant during the study
* Patient taking medication that interferes with interpretation of study results such as chronic corticosteroid therapy
* Patient with a chimio - or radiotherapy is in progress or is planned
* Patient abusing substances
* Patient who participated in another clinical study in the four weeks prior to inclusion
* Patient with or suspected of having any physical, psychological or cognitive disorders interfering with adherence to insulin therapy by pump, or compliance with dietary advice, or completion of the patient's diary
* Patient unable to comply with clinical guidelines, and unable to comply with 3-month follow-up
* Patient unable to understand information, to sign informed consent or to manage glycemic sensor
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Reims, France
UNKNOWN
Central Hospital, Toulouse, France
UNKNOWN
Central Hospital, Strasbourg, France
UNKNOWN
Central Hospital, Besançon, France
UNKNOWN
Central Hospital, Dijon, France
UNKNOWN
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service d'Endocrinologie-Métabolisme et Diabétologie-Nutrition
Besançon, , France
Service d'endocrinologie et maladies métaboliques
Dijon, , France
Service d'Endocrinologie, Diabétologie et Nutrition
Nancy, , France
Service Endocrinologie Diabète Nutrition
Reims, , France
Structure d'Endocrinologie, Diabète et Nutrition
Strasbourg, , France
Service de diabétologie, maladies métaboliques et nutrition
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A02414-49
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.